First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Reaches New 1-Year High – What’s Next?

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) reached a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $44.83 and last traded at $44.3310, with a volume of 16,407 shares. The stock had previously closed at $43.87.

First Trust Nasdaq Pharmaceuticals ETF Price Performance

The company’s fifty day moving average price is $41.74 and its 200 day moving average price is $37.29. The company has a market cap of $1.19 billion, a PE ratio of 14.51 and a beta of 0.45.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Thursday, September 24th were given a $0.0113 dividend. This is a negative change from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.0920. This represents a $0.05 annualized dividend and a yield of 0.1%. The ex-dividend date of this dividend was Thursday, September 24th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Englebert Financial Advisers LLC purchased a new position in First Trust Nasdaq Pharmaceuticals ETF in the third quarter valued at approximately $751,000. Oppenheimer & Co. Inc. purchased a new stake in First Trust Nasdaq Pharmaceuticals ETF in the third quarter worth $6,014,000. Cyndeo Wealth Partners LLC purchased a new stake in First Trust Nasdaq Pharmaceuticals ETF in the third quarter worth $1,524,000. Trust Co. of Oklahoma bought a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF in the third quarter valued at $1,283,000. Finally, D.A. Davidson & CO. bought a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF in the third quarter valued at $3,702,000.

About First Trust Nasdaq Pharmaceuticals ETF

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.